580 related articles for article (PubMed ID: 32919903)
21. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
[TBL] [Abstract][Full Text] [Related]
22. Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.
Grumach AS; Henriques MT; Bardou MLD; Pontarolli DA; Botha J; Correa M;
An Bras Dermatol; 2022; 97(4):448-457. PubMed ID: 35654647
[TBL] [Abstract][Full Text] [Related]
23. Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients.
Sobotkova M; Zachova R; Hakl R; Kuklinek P; Kralickova P; Krcmova I; Hanzlikova J; Vachova M; Bartunkova J
Int Arch Allergy Immunol; 2021; 182(7):642-649. PubMed ID: 33472202
[TBL] [Abstract][Full Text] [Related]
24. Hereditary and acquired angioedema.
Patel G; Pongracic JA
Allergy Asthma Proc; 2019 Nov; 40(6):441-445. PubMed ID: 31690390
[TBL] [Abstract][Full Text] [Related]
25. Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States.
Riedl MA; Banerji A; Manning ME; Burrell E; Joshi N; Patel D; Machnig T; Tai MH; Watson DJ
Orphanet J Rare Dis; 2018 Oct; 13(1):180. PubMed ID: 30314518
[TBL] [Abstract][Full Text] [Related]
26. [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results].
Kawalec P; Holko P; Paszulewicz A; Obtułowicz K
Pneumonol Alergol Pol; 2013; 81(2):95-104. PubMed ID: 23420425
[TBL] [Abstract][Full Text] [Related]
27. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C
Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and treatment of hereditary angioedema.
Canonica GW; Rossi O
Panminerva Med; 2012 Sep; 54(3):241-53. PubMed ID: 22801442
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
[TBL] [Abstract][Full Text] [Related]
30. Is Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy?
Šimac DV; Štimac T; Novak S
Curr Allergy Asthma Rep; 2022 Oct; 22(10):135-140. PubMed ID: 36044174
[TBL] [Abstract][Full Text] [Related]
31. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
32. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.
Jacobs J; Neeno T
Postgrad Med; 2021 Aug; 133(6):639-650. PubMed ID: 33993830
[TBL] [Abstract][Full Text] [Related]
33. Icatibant for hereditary angioedema.
Gras J
Drugs Today (Barc); 2009 Dec; 45(12):855-64. PubMed ID: 20135020
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting.
Craig TJ; Bernstein JA; Farkas H; Bouillet L; Boccon-Gibod I
Int Arch Allergy Immunol; 2014; 165(2):119-27. PubMed ID: 25401373
[TBL] [Abstract][Full Text] [Related]
35. Chapter 22: Hereditary and acquired angioedema.
Georgy MS; Pongracic JA
Allergy Asthma Proc; 2012; 33 Suppl 1():73-76. PubMed ID: 22794695
[TBL] [Abstract][Full Text] [Related]
36. How satisfactory is on-demand icatibant from the patients' perspective in real life?
Beyaz S; Demir S; Oztop N; Colakoglu B; Buyukozturk S; Gelincik A
Allergy Asthma Proc; 2022 Mar; 43(2):148-154. PubMed ID: 35317892
[No Abstract] [Full Text] [Related]
37. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency.
Zanichelli A; Azin GM; Wu MA; Suffritti C; Maggioni L; Caccia S; Perego F; Vacchini R; Cicardi M
J Allergy Clin Immunol Pract; 2017; 5(5):1307-1313. PubMed ID: 28284781
[TBL] [Abstract][Full Text] [Related]
39. Treatment of hereditary angioedema: a review (CME).
Bhardwaj N; Craig TJ
Transfusion; 2014 Nov; 54(11):2989-96; quiz 2988. PubMed ID: 24735226
[TBL] [Abstract][Full Text] [Related]
40. Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years.
Farkas H; Kőhalmi KV
Expert Rev Clin Immunol; 2018 Jun; 14(6):447-460. PubMed ID: 29757016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
